SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (524)2/5/2000 1:21:00 PM
From: Vector1  Read Replies (1) | Respond to of 666
 
Biowa,
You had me nodding my head in agreement until the last sentence.
<<Net: If efficacy is the primary issue, IMHO Rit should win, otherwise it becomes a marketing battle>>

I think you meant Bex should win.
V1



To: biowa who wrote (524)2/5/2000 1:22:00 PM
From: Miljenko Zuanic  Respond to of 666
 
<<Net: If efficacy is the primary issue, IMHO Rit should win, otherwise it becomes a marketing battle.>>

At this point I will give small edge to Rit, reasons you already mentioned. However, now when SKB and GLX are one entity (very strong marketing machinery) , imo, it will be marketing battle, worldwide.

SCREW AVALON!!!

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News